Karuna Announces First Consumer Dosed In Phase 2 Study Of Lead Product Candidate KarXT For The Treatment Of Schizophrenia

Clinical-stage drug development company Karuna Pharmaceuticals (Karuna) recently announced it is initiating a phase 2 study to evaluate the efficacy and safety of KarXT. KarXT (Karuna-Xanomeline-Trospium) is Karuna’s lead investigational product candidate for the treatment of psychosis in schizophrenia.

In previous studies, KarXT showed to be well-tolerated by participants in dose levels exceeding those shown to be effective in past studies involving xanomeline. According to statements from Karuna’s CEO, Steve Paul, M.D., KarXT has the potential to become the first antipsychotic drug with a unique mechanism in over 60 years which could be . . .